Introduction
Inhibition of unwanted hair growth is one of the major concerns in skincare, and a wide variety of approaches have been used toward this goal. We examined whether ribosome-inactivating protein (RIP) ricin and related abrin can be used to inhibit hair growth on topical application. Ricin, a well-known plant-derived protein, inactivates eukaryotic ribosomes by modifying two nucleoside residues, G4323 and A4324, in 28 S rRNA [1] . Ricin and the other members of this toxin family are very efficient at cell killing. Ricin is known to activate ribotoxic stress-induced SAPK signaling pathways [2] as well as p38 [3] . Moreover, ricin was shown to induce IGFBP-3 expression through the p38 signaling pathway [4] leading to cytokine secretion. However, earlier reports indicated that amount of ricin absorbed through skin is so negligible that it is considered to be dermally inactive [5] , as no dermal toxicity was observed at 50 μg/spot during skin tests on mice [6] . Therefore, toxicity by this route is suggested to be unachievable by Schep et al. [7] . Earlier studies using crude ricinus extracts and purified ricin [8] had indicated that ricin inhibits hair growth when applied topically. All mature hair follicles show a cyclic pattern consisting of phases of growth (anagen), regression (catagen), rest (telogen), and shedding (exogen). The anagen hair follicle consists of a so-called permanent portion at the bulge region above the muscle insertion and a cycling portion below [9] . Though ricin and related cytotoxic lectin abrin were considered to be dermally inactive, the observations of the present study suggest that they have potential to induce hair follicle dystrophy resulting into reduced rate and altered character of hair regrowth, keeping all other skin structures intact. Present study corroborates earlier findings [8] that cytotoxic lectins like ricin are not completely dermally inactive as perceived [5] [7] but instead inhibit the growth of hair follicle, keeping all other skin structures intact. The present findings provide a rationale for further investigations using hair follicle as a dynamic regenerative mini-organ with a cyclic growth pattern, to determine the dermal role of ricin and related proteins, as a model for programmed organ deletion. Phase I clinical trials of ricin [10] and abrin [11] There is no significant change in ricin-treated sections when compared to untreated sections with respect to inflammatory changes. Table 1 . Hair follicles were divided in seven groups with one control group (distilled water); eflornithine (two doses: 400 and 1,000 μg/mL); ricin (two doses: 40 and 100 μg/mL); and abrin (two doses: 40 and 100 μg/mL).
Results & Discussion
Purification of ricin:Ricin was purified by affinity chromatography ( Figure 1A ), and purity of pooled ricin fractions was assessed by SDS-PAGE ( Figure 1B ). LC-MS of aqueous extract of castor bean showed ricin peaks at 6.881 min ( Figure 1C ). Deconvolution of LC-MS spectrum estimated a molecular weight of 64,831.42 Da for ricin ( Figure 1D ).
Pilot studies to assess topical effect of ricin and abrin: When compared to control patches (Figure 2A ),hair regrowth on all the test patches of BALB/C mice was delayed and sparse ( Figure 2B ). The untreated hair follicles show normal ladder-like structure ( Figure 2C ). The difference in terms of inhibition of hair regrowth and hair follicle dystrophy was visible in histological picture as early as 10 days after the topical application of ricin ( Figure 2D ). Histopathology sections studied from all the biopsies showed no adverse reaction to other skin structures. All the ricin-treated sections after 30 days of treatment showed dose-dependent reduction in number of hair follicles as compared to the control ( Figure 2E-H) . Some of the hair follicles from the test samples appeared empty, whereas some of them showed hair follicle dystrophy wherein the normal ladderlike structure of the hair shaft was disturbed. Similarly, as compared to control sections ( Figure 2I ) abrin-treated sections show less number of HFs, and HF dystrophy ( Figure  2J ). Assessment of hair follicle dystrophy caused by ricin in mice:Effect of topical treatment of ricin was assessed in C57BL/6 female mouse model, which is a standard mouse model for hair growth studies ( Figure 3A) . Difference between the dystrophy scores of normal healthy anagen hair follicles in control areas and the dystrophic anagen or dystrophic catagen hair follicles in the test areas in each animal persisted throughout the study period of 20 days (p <0.0032**) (n=60 C57BL/6 mice) ( Figure 3B ). The HF growth cycle appeared to be shortened with early recovery followed by dystrophic hair follicles. In response to topical treatment of ricin for 10 days after inducing anagen by depilation, instead of entering a new growth cycle with a healthy anagen as compared to control section ( Figure 3C(a) ), the ricin-treated HFs immediately responded by showing characteristic features of dystrophy on day 5 ( Figure 3C(k) ). All the HFs in test groups at each time point showed various stages of dystrophic HFs with half of the HFs being in early dystrophic anagen VI. At each time point, the HFs of the control area of the same animal showed healthy stage of HF growth cycle ( Figure 3CA(a-j) ). The ricintreated HFs showed classical features of chemotherapy induced HF dystrophy [13] such as number of ectopic melanin granules, follicular and hair shaft distortion; and irregular diameter of hair bulbs (Supplementary Figure 2) . The point should be noted that these variations in HF growth stage and presence of HF dystrophy are observed in untreated and ricin-treated areas of the same animaland localized effect of HF dystrophy was achieved.
In vitro organ-cultured human HF studies:During the examination of cultured human HFs under a light microscope, HFs were assessed for changes in hair shaft elongation and classified according to classical parameters for hair cycle stage as described by Müller-Röver and Klopper [14] [15] . Parameters for this classification of hair follicle cycle stage were shape and size of hair matrix (HM) and dermal papilla (DP). The human HFs in vitro responded to treatment of ricin in line with our findings in animal studies. The hair shaft elongation was significantly less in both groups of ricin-and abrin-treated HFs with both the dose levels when compared to control group. (MannWhitney test for unpaired samples:ricin (R40 -p <0.0001***, R100 -p <0.0027**) and abrin (AB40 -p <0.0003***, AB100 -p <0.0001***)) ( Figure 4A ). Ricin-treated HFs showed classic parameters of dystrophic catagen induction whereas the hair follicles in control group were healthy. Similarly, HFs treated with abrin too showed dystrophic catagen induction. Eflornithine-treated HFs are assessed for morphological parameters and compared with ricin and abrin-treated HFs. Eflornithine-treated HFs showed catagen induction. This observation was confirmed with DAPI staining for presence of less number of DAPI+ cells below Auber's line (an imaginary line that separates the HF bulb at widest part of dermal papilla, the region below this line contains pluripotent stem cells with high mitotic activity and is the germination region) in ricin and abrin-treated group as compared to control and eflornithine group ( Figure 4B ).Effect of topical ricin and abrin treatment in the form of dystrophy and reduced number of DAPI+ cells in this germination region indicates a possible mechanism of action on pluripotent stem cells. Preclinical toxicological studies of ricin and abrin: Acute oral toxicity test of ricin (200 μg/mL) solution were found to be safe at 2 mg/kg body weight. No clinical signs of intoxication were observed in any animal till the end of the study and no mortality observed. Acute dermal toxicity test (14 days) with ricin (200 μg/mL) was found to be safe at 2 mg/kg body weight. All the animals appeared normal and showed no clinical signs of intoxication. No change in food consumption was observed. Subacute dermal toxicity test (90 days) with ricin (200 μg/mL) and abrin (200 μg/mL) was found to be safe ( Figure  5 ). All the animals appeared normal and showed no clinical signs of intoxication. No change in food consumption was observed. No significant difference in hematology and blood chemistry parameters was observed in the test group as compared to the control group (Supplementary Fig 1) . The histopathology of liver, kidney, and heart did not show any toxicity (Supplementary Fig.1 ). Ricin was found to be safe for sub-acute dermal test for 90 days for a dose equivalent to human dose of 160 μg/kg each [16] . Discussion:It has been reported earlier that no dermal toxicity was observed during skin tests on mice at 50 μg/spot [5] . Though ricin and related proteins were widely considered to be dermally inactive earlier, our observations indicate the dermal role of ricin and abrin in HF dystrophy at comparatively very low dose levels, resulting in hair growth inhibition. Our observations during in vivo animal studies and in vitro human HF organ culture studies indicate HF dystrophy induction by ricin. Observations during preclinical toxicology studies indicate that ricin by topical route of administration at given dose level was found to be safe for use without adversely affecting any other skin structures. Repeated induction of dystrophy may result in reduction of the regrowth of unwanted HFs. Hence, we propose ricin to be a promising candidate for inhibiting growth of unwanted hair follicles. We propose that common molecular players involved in ricin-induced cell death and those involved in growth modulation of hair follicle, such as IGF- [27] . Our findings suggest topical ricin formulations have potential to reduce the rate and character of hair growth, offering a long-lasting relief to the user.
The scientific findings of this study present a possibility of creating a new treatment for unwanted hair, an unmet need in cosmetic industry. So far, ricin was considered to be a toxic waste product of castor oil industry with no therapeutic value. Moreover, in spite of numerous reports and articles denying it having any such potential to be weaponized [6] [7] , it is perceived to be a weapon of mass destruction, labeled as an ugly duckling and classified as Category B select agent [28] . With this new-found therapeutic potential by dermal route, this ugly duckling has matured and begun to look a little more like a swan. These are preliminary observations showing the therapeutic potential of ricin and related proteins. The exact role of ricin on the molecular mechanisms of hair follicle is not known; however, the present findings provide a preliminary basis to investigate further the molecular mechanisms involved in HF dystrophy induced by ricin and related protein abrin. To propose a systematic molecular model of damage response of the hair follicle to topical treatment, extensive studies with a sufficiently large sample size is needed. Assessment of apoptotic vs. cytotoxic markers in the hair follicle culture experiments would have been more insightful. Dose-response analysis over a wide dose range is required to arrive at an optimum dose range of ricin. Further studies are planned to explore the clinical applicability of ricin and related proteins in hirsutism treatment.
Additional Information
Methods and Supplementary Material Please see https://sciencematters.io/articles/201702000001. This study was self-funded by first author. 
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